Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.
Prasad M, Zorea J, Jagadeeshan S, Shnerb AB, Mathukkada S, Bouaoud J, Michon L, Novoplansky O, Badarni M, Cohen L, Yegodayev KM, Tzadok S, Rotblat B, Brezina L, Mock A, Karabajakian A, Fayette J, Cohen I, Cooks T, Allon I, Dimitstein O, Joshua B, Kong D, Voronov E, Scaltriti M, Carmi Y, Conde-Lopez C, Hess J, Kurth I, Morris LGT, Saintigny P, Elkabets M. Prasad M, et al. Among authors: saintigny p. J Immunother Cancer. 2022 Mar;10(3):e003917. doi: 10.1136/jitc-2021-003917. J Immunother Cancer. 2022. PMID: 35292516 Free PMC article.
Chemotherapy for localized head and neck squamous cell cancers.
Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, Fayette J. Karabajakian A, et al. Among authors: saintigny p. Anticancer Drugs. 2017 Apr;28(4):362-368. doi: 10.1097/CAD.0000000000000480. Anticancer Drugs. 2017. PMID: 28134662 Review.
Chemotherapy for recurrent/metastatic head and neck cancers.
Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, Fayette J. Karabajakian A, et al. Among authors: saintigny p. Anticancer Drugs. 2017 Apr;28(4):357-361. doi: 10.1097/CAD.0000000000000473. Anticancer Drugs. 2017. PMID: 28166090 Review.
The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.
Foy JP, Bertolus C, Michallet MC, Deneuve S, Incitti R, Bendriss-Vermare N, Albaret MA, Ortiz-Cuaran S, Thomas E, Colombe A, Py C, Gadot N, Michot JP, Fayette J, Viari A, Van den Eynde B, Goudot P, Devouassoux-Shisheboran M, Puisieux A, Caux C, Zrounba P, Lantuejoul S, Saintigny P. Foy JP, et al. Among authors: saintigny p. Ann Oncol. 2017 Aug 1;28(8):1934-1941. doi: 10.1093/annonc/mdx210. Ann Oncol. 2017. PMID: 28460011 Free article.
New insights into the role of EMT in tumor immune escape.
Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, Thiery JP, Chouaib S. Terry S, et al. Among authors: saintigny p. Mol Oncol. 2017 Jul;11(7):824-846. doi: 10.1002/1878-0261.12093. Epub 2017 Jun 27. Mol Oncol. 2017. PMID: 28614624 Free PMC article. Review.
mTOR Signalling in Head and Neck Cancer: Heads Up.
Tan FH, Bai Y, Saintigny P, Darido C. Tan FH, et al. Among authors: saintigny p. Cells. 2019 Apr 9;8(4):333. doi: 10.3390/cells8040333. Cells. 2019. PMID: 30970654 Free PMC article. Review.
AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity.
Terry S, Abdou A, Engelsen AST, Buart S, Dessen P, Corgnac S, Collares D, Meurice G, Gausdal G, Baud V, Saintigny P, Lorens JB, Thiery JP, Mami-Chouaib F, Chouaib S. Terry S, et al. Among authors: saintigny p. Cancer Immunol Res. 2019 Nov;7(11):1789-1802. doi: 10.1158/2326-6066.CIR-18-0903. Epub 2019 Sep 5. Cancer Immunol Res. 2019. PMID: 31488404
139 results